Form 4: Enanta Pharmaceuticals Executive Paul J. Mellett Reports Changes in Beneficial Ownership

Paul J. Mellett, Chief Financial & Administrative Officer of Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares of common stock on February 12, 2025.

Summary

• On February 12, 2025, Paul J. Mellett, the Chief Financial & Administrative Officer of Enanta Pharmaceuticals, acquired 7,500 shares of common stock.
• These shares were issued under performance share units (PSUs) that vested due to the achievement of two-year research and development milestones in the 2023-2024 period.
• The Compensation Committee of Enanta's Board of Directors determined the vesting of these PSUs.
• On the same day, Mellett disposed of 3,326 shares of common stock at a price of $5.59 per share.
• These shares were automatically forfeited to cover withholding taxes due to the settlement of the PSU awards.
• Following these transactions, Mellett beneficially owns 95,884 shares of Enanta common stock.

Sentiment

Score: 6

Explanation: The document primarily reports routine transactions related to executive compensation. The vesting of PSUs suggests positive performance, but the tax-related disposal is neutral.

Positives

• The vesting of performance share units indicates the achievement of research and development milestones, which is a positive sign for the company's progress.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, ensuring fair market practices.

Stakeholder Impact

• The vesting of PSUs and subsequent share transactions can influence investor sentiment, though the impact is likely to be minor given the routine nature of the filing.

Key Dates